Gastrin I (human): Mechanistic Insights for Gastric Acid Secretion and CCK2 Signaling Research

Executive Summary: Gastrin I (human) is a synthetic peptide corresponding to the sequence of human gastrin, with a molecular weight of 2098.22 Da and CAS number 10047-33-3 (APExBIO). It is a potent gastric acid secretion regulator, acting as a CCK2 receptor (cholecystokinin B receptor) agonist that triggers proton pump activation in gastric parietal cells (Saito et al., 2025). This peptide is widely used in vitro to dissect receptor-mediated signal transduction and gastrointestinal physiology, especially in hiPSC-derived organoid models. Stringent quality control (≥98% purity by HPLC and MS) ensures high reproducibility for pharmacological and mechanistic studies. Storage and solubility parameters are well defined, supporting robust experimental workflows.

Biological Rationale

Gastrin I (human) is a regulatory peptide naturally produced in the G cells of the stomach antrum. Its primary physiological role is to stimulate gastric acid secretion by acting on specific receptors located on the surface of gastric parietal cells (Dimesna Review). Upon binding to the CCK2 receptor (also known as the gastrin/CCK-B receptor), Gastrin I initiates a signaling cascade leading to increased proton secretion. This process is essential for digestion and maintaining gastric pH homeostasis. Insights into this pathway are crucial for understanding gastrointestinal physiology and the pathogenesis of acid-related disorders. Human pluripotent stem cell-derived intestinal organoids have emerged as a powerful in vitro model to study these regulatory mechanisms, offering a human-relevant platform for pharmacodynamics and pharmacokinetics (Saito et al., 2025).

Mechanism of Action of Gastrin I (human)

Gastrin I (human) functions as a high-affinity agonist for the CCK2 receptor. Upon ligand binding, the receptor undergoes conformational changes that activate intracellular G-proteins. This leads to the stimulation of phospholipase C (PLC), resulting in the production of inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C (PKC). The resulting increase in cytosolic calcium and PKC activity promotes the activation of the H⁺/K⁺-ATPase (proton pump) on the parietal cell membrane. This cascade culminates in the secretion of hydrochloric acid (HCl) into the gastric lumen (Prescission Review). The process is tightly regulated, and aberrations can lead to clinical conditions such as peptic ulcer disease or Zollinger-Ellison syndrome.

Evidence & Benchmarks

• Gastrin I (human) at concentrations of 10^-9 to 10^-7 M reliably induces gastric acid secretion in isolated human parietal cells in vitro (Saito et al., 2025).
• Binding affinity (K_d) for human CCK2 receptor is in the low nanomolar range, ensuring specificity in signal transduction studies (Prescission Review).
• High-purity (>98%) Gastrin I (human) verified by HPLC and MS supports reproducible pharmacological modeling (APExBIO).
• In hiPSC-derived intestinal organoids, Gastrin I (human) application results in upregulation of acid secretion pathway genes within 2–6 hours (Saito et al., 2025).
• Product is insoluble in water and ethanol but fully dissolves in DMSO at concentrations ≥21 mg/mL, maintaining stability at -20°C under desiccated conditions (APExBIO).

This article updates and extends the guidance provided in 'Precision Tools for Gastric Acid Pathways' by detailing stricter solubility thresholds and purity verification protocols for Gastrin I (human).

Applications, Limits & Misconceptions

Gastrin I (human) is employed extensively as a research tool in the following areas:

• Gastric acid secretion pathway research—Characterization of acid secretion dynamics and parietal cell signaling.
• Gastrointestinal physiology studies—Modeling normal and pathological acid secretion in organoid systems.
• Gastrointestinal disorder research—Investigation of proton pump activation mechanisms relevant to disorders like peptic ulcers.
• CCK2 receptor signaling—Benchmarking agonist potency and receptor response in engineered cell lines and hiPSC-derived models.

This article clarifies and expands upon findings in 'Precision Modeling of CCK2 Signaling' by integrating recent benchmarks from hiPSC-derived organoid experiments.

Common Pitfalls or Misconceptions

• Gastrin I (human) is not effective in non-CCK2-expressing systems; its activity is limited to cells with functional CCK2 receptors.
• It does not directly activate proton pumps; it acts through signal transduction pathways requiring intact G-protein and PLC activity.
• Product is insoluble in aqueous buffers and ethanol; improper dissolution can lead to loss of function.
• Long-term storage of solutions is not recommended; stability is compromised beyond 24 hours even at -20°C.
• Use in animal models may not fully recapitulate human-specific signaling due to species receptor differences (Saito et al., 2025).

Workflow Integration & Parameters

For experimental use, Gastrin I (human) (SKU: B5358, APExBIO) is supplied as a white, lyophilized solid. The product is insoluble in water and ethanol but dissolves in DMSO at ≥21 mg/mL. Reconstituted solutions should be prepared fresh and used immediately, as prolonged storage leads to degradation. The recommended storage condition is desiccated at -20°C. Experimental concentrations typically range from 1 nM to 1 μM, depending on assay sensitivity and receptor expression levels. For gastrointestinal organoid applications, dosing should be optimized based on organoid density and receptor profiling. Refer to 'Mechanistic Mastery and Translational Vision' for advanced design considerations integrating Gastrin I with pharmacokinetics and translational endpoints.

Conclusion & Outlook

Gastrin I (human) is a pivotal tool for dissecting the mechanisms of gastric acid secretion and CCK2 receptor signaling in human-relevant models. Stringent quality control, high purity, and defined solubility/storage parameters underpin its value in reproducible research. Integration with hiPSC-derived organoid systems enables new frontiers in gastrointestinal physiology and disorder modeling. Ongoing research will likely expand its utility in drug discovery and translational studies aiming to modulate gastric function. For product details, refer to the official APExBIO product page.